Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Insulet Corporation logo
PODD

Insulet Corporation

MaveScore 30 Low model confidence
Last Price US$147.35 As of Jun 16, 2026
Market Cap US$10.8b Company size context
7D Performance -8.41% Past 7 days
1Y Performance -51.18% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

77 days old

Market price date

Jun 16, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 30 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

18/35 Mixed

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

11/25 Mixed

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

1/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

0/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
  • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.
  • Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Insulet Corporation Overview

Industry: Healthcare Equipment & Supplies

Sector: Healthcare

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Insulet Corporation in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Insulet Corporation Competitors

Insulet Corporation operates in the Healthcare Equipment & Supplies industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Insulet Corporation

US$147.35

US$10.8b

-8.41%

-51.18%